Abstract
The antitumor activity of a novel nucleoside, 1-(2-deoxy-2-fluoro-4-thio-β- d arabinofuranosyl)cytosine (4′-thio-FAC) was compared with that of 2′-deoxy-2′,2′-difluorocytidine (gemcitabine). 4′-Thio-FAC showed potent antitumor effects against various solid cancer cell lines in vitro. Also, gemcitabine showed remarkable in vitro antitumor effects, even more potent than 4′-thio-FAC. However, 4′-thio-FAC inhibited tumor growth more strongly than gemcitabine did at the same dose against human cancer cells implanted s.c. in nude mice. In addition, 4′-thio-FAC suppressed the tumor growth by oral administration. The toxicity of 4′-thio-FAC was weaker than that of gemcitabine in nude mice in both consecutive and intermittent administration. Accordingly, clinical usefulness of 4′-thio-FAC is expected.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
